Argatroban tPA stroke study: Study design and results in the first treated cohort

Rebecca M. Sugg, Jennifer K. Pary, Ken Uchino, Sarah Baraniuk, Hashem Shaltoni, Nicole R. Gonzales, Robert Mikulik, Zsolt Garami, Sandi G. Shaw, Dawn E. Matherne, Lemuel A. Moyé, Andrei V. Alexandrov, James C. Grotta

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Background: The benefit of intravenous recombinant tissue plasminogen activator (rtPA) in acute stroke is linked to clot lysis and artery recanalization. Argatroban is a direct thrombin inhibitor that safely augments the benefit of rtPA in animal stroke models. There are no human data on this combination. Design: We report the first phase of the Argatroban tPA Stroke Study, an ongoing prospective, open-label, dose-escalation, safety and activity study of argatroban and rtPA in patients with ischemic stroke. The primary outcome was incidence of intracerebral hemorrhage; secondary outcome, complete recanalization at 2 hours. After standard-dose intravenous rtPA administration, a 100-μg/kg bolus of argatroban followed by infusion of 1 μg/kg per minute for 48 hours was adjusted to a target partial thromboplastin time of 1.75 times that of the control group. Results: Fifteen patients (including 10 men) were enrolled, with a mean±SD age of 61±13 years. All patients had middle cerebral artery occlusions. Baseline median National Institute of Health Stroke Scale score was 14 (range, 4-25). The mean±SD time from symptom onset to argatroban bolus administration was 172±53 minutes. Symptomatic intracerebral hemorrhage occurred in 2 patients, including 1 with parenchymal hemorrhage type 2. Asymptomatic bleeding occurred in 1 patient and there was 1 death. Recanalization was complete in 6 patients and partial in another 4, and reocclusion occurred in 3 within 2 hours of rtPA bolus administration. Conclusion: The safety of low-dose argatroban combined with intravenous rtPA may be within acceptable limits, and its efficacy for producing fast and complete recanalization is promising, but a larger cohort of patients is required to confirm these preliminary observations. Trial Registration: clinicaltrials.gov Identifier: NCT00268762.

Original languageEnglish (US)
Pages (from-to)1057-1062
Number of pages6
JournalArchives of Neurology
Volume63
Issue number8
DOIs
StatePublished - Aug 1 2006
Externally publishedYes

Fingerprint

Tissue Plasminogen Activator
Stroke
Cerebral Hemorrhage
Hemorrhage
Safety
Antithrombins
Partial Thromboplastin Time
Middle Cerebral Artery Infarction
National Institutes of Health (U.S.)
argatroban
Cohort
Animal Models
Arteries
Prospective Studies
Control Groups
Incidence
Dose

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Sugg, R. M., Pary, J. K., Uchino, K., Baraniuk, S., Shaltoni, H., Gonzales, N. R., ... Grotta, J. C. (2006). Argatroban tPA stroke study: Study design and results in the first treated cohort. Archives of Neurology, 63(8), 1057-1062. https://doi.org/10.1001/archneur.63.8.1057

Argatroban tPA stroke study : Study design and results in the first treated cohort. / Sugg, Rebecca M.; Pary, Jennifer K.; Uchino, Ken; Baraniuk, Sarah; Shaltoni, Hashem; Gonzales, Nicole R.; Mikulik, Robert; Garami, Zsolt; Shaw, Sandi G.; Matherne, Dawn E.; Moyé, Lemuel A.; Alexandrov, Andrei V.; Grotta, James C.

In: Archives of Neurology, Vol. 63, No. 8, 01.08.2006, p. 1057-1062.

Research output: Contribution to journalArticle

Sugg, RM, Pary, JK, Uchino, K, Baraniuk, S, Shaltoni, H, Gonzales, NR, Mikulik, R, Garami, Z, Shaw, SG, Matherne, DE, Moyé, LA, Alexandrov, AV & Grotta, JC 2006, 'Argatroban tPA stroke study: Study design and results in the first treated cohort', Archives of Neurology, vol. 63, no. 8, pp. 1057-1062. https://doi.org/10.1001/archneur.63.8.1057
Sugg, Rebecca M. ; Pary, Jennifer K. ; Uchino, Ken ; Baraniuk, Sarah ; Shaltoni, Hashem ; Gonzales, Nicole R. ; Mikulik, Robert ; Garami, Zsolt ; Shaw, Sandi G. ; Matherne, Dawn E. ; Moyé, Lemuel A. ; Alexandrov, Andrei V. ; Grotta, James C. / Argatroban tPA stroke study : Study design and results in the first treated cohort. In: Archives of Neurology. 2006 ; Vol. 63, No. 8. pp. 1057-1062.
@article{0292ab5eb4824b82a0b0f6bba829358c,
title = "Argatroban tPA stroke study: Study design and results in the first treated cohort",
abstract = "Background: The benefit of intravenous recombinant tissue plasminogen activator (rtPA) in acute stroke is linked to clot lysis and artery recanalization. Argatroban is a direct thrombin inhibitor that safely augments the benefit of rtPA in animal stroke models. There are no human data on this combination. Design: We report the first phase of the Argatroban tPA Stroke Study, an ongoing prospective, open-label, dose-escalation, safety and activity study of argatroban and rtPA in patients with ischemic stroke. The primary outcome was incidence of intracerebral hemorrhage; secondary outcome, complete recanalization at 2 hours. After standard-dose intravenous rtPA administration, a 100-μg/kg bolus of argatroban followed by infusion of 1 μg/kg per minute for 48 hours was adjusted to a target partial thromboplastin time of 1.75 times that of the control group. Results: Fifteen patients (including 10 men) were enrolled, with a mean±SD age of 61±13 years. All patients had middle cerebral artery occlusions. Baseline median National Institute of Health Stroke Scale score was 14 (range, 4-25). The mean±SD time from symptom onset to argatroban bolus administration was 172±53 minutes. Symptomatic intracerebral hemorrhage occurred in 2 patients, including 1 with parenchymal hemorrhage type 2. Asymptomatic bleeding occurred in 1 patient and there was 1 death. Recanalization was complete in 6 patients and partial in another 4, and reocclusion occurred in 3 within 2 hours of rtPA bolus administration. Conclusion: The safety of low-dose argatroban combined with intravenous rtPA may be within acceptable limits, and its efficacy for producing fast and complete recanalization is promising, but a larger cohort of patients is required to confirm these preliminary observations. Trial Registration: clinicaltrials.gov Identifier: NCT00268762.",
author = "Sugg, {Rebecca M.} and Pary, {Jennifer K.} and Ken Uchino and Sarah Baraniuk and Hashem Shaltoni and Gonzales, {Nicole R.} and Robert Mikulik and Zsolt Garami and Shaw, {Sandi G.} and Matherne, {Dawn E.} and Moy{\'e}, {Lemuel A.} and Alexandrov, {Andrei V.} and Grotta, {James C.}",
year = "2006",
month = "8",
day = "1",
doi = "10.1001/archneur.63.8.1057",
language = "English (US)",
volume = "63",
pages = "1057--1062",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "8",

}

TY - JOUR

T1 - Argatroban tPA stroke study

T2 - Study design and results in the first treated cohort

AU - Sugg, Rebecca M.

AU - Pary, Jennifer K.

AU - Uchino, Ken

AU - Baraniuk, Sarah

AU - Shaltoni, Hashem

AU - Gonzales, Nicole R.

AU - Mikulik, Robert

AU - Garami, Zsolt

AU - Shaw, Sandi G.

AU - Matherne, Dawn E.

AU - Moyé, Lemuel A.

AU - Alexandrov, Andrei V.

AU - Grotta, James C.

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Background: The benefit of intravenous recombinant tissue plasminogen activator (rtPA) in acute stroke is linked to clot lysis and artery recanalization. Argatroban is a direct thrombin inhibitor that safely augments the benefit of rtPA in animal stroke models. There are no human data on this combination. Design: We report the first phase of the Argatroban tPA Stroke Study, an ongoing prospective, open-label, dose-escalation, safety and activity study of argatroban and rtPA in patients with ischemic stroke. The primary outcome was incidence of intracerebral hemorrhage; secondary outcome, complete recanalization at 2 hours. After standard-dose intravenous rtPA administration, a 100-μg/kg bolus of argatroban followed by infusion of 1 μg/kg per minute for 48 hours was adjusted to a target partial thromboplastin time of 1.75 times that of the control group. Results: Fifteen patients (including 10 men) were enrolled, with a mean±SD age of 61±13 years. All patients had middle cerebral artery occlusions. Baseline median National Institute of Health Stroke Scale score was 14 (range, 4-25). The mean±SD time from symptom onset to argatroban bolus administration was 172±53 minutes. Symptomatic intracerebral hemorrhage occurred in 2 patients, including 1 with parenchymal hemorrhage type 2. Asymptomatic bleeding occurred in 1 patient and there was 1 death. Recanalization was complete in 6 patients and partial in another 4, and reocclusion occurred in 3 within 2 hours of rtPA bolus administration. Conclusion: The safety of low-dose argatroban combined with intravenous rtPA may be within acceptable limits, and its efficacy for producing fast and complete recanalization is promising, but a larger cohort of patients is required to confirm these preliminary observations. Trial Registration: clinicaltrials.gov Identifier: NCT00268762.

AB - Background: The benefit of intravenous recombinant tissue plasminogen activator (rtPA) in acute stroke is linked to clot lysis and artery recanalization. Argatroban is a direct thrombin inhibitor that safely augments the benefit of rtPA in animal stroke models. There are no human data on this combination. Design: We report the first phase of the Argatroban tPA Stroke Study, an ongoing prospective, open-label, dose-escalation, safety and activity study of argatroban and rtPA in patients with ischemic stroke. The primary outcome was incidence of intracerebral hemorrhage; secondary outcome, complete recanalization at 2 hours. After standard-dose intravenous rtPA administration, a 100-μg/kg bolus of argatroban followed by infusion of 1 μg/kg per minute for 48 hours was adjusted to a target partial thromboplastin time of 1.75 times that of the control group. Results: Fifteen patients (including 10 men) were enrolled, with a mean±SD age of 61±13 years. All patients had middle cerebral artery occlusions. Baseline median National Institute of Health Stroke Scale score was 14 (range, 4-25). The mean±SD time from symptom onset to argatroban bolus administration was 172±53 minutes. Symptomatic intracerebral hemorrhage occurred in 2 patients, including 1 with parenchymal hemorrhage type 2. Asymptomatic bleeding occurred in 1 patient and there was 1 death. Recanalization was complete in 6 patients and partial in another 4, and reocclusion occurred in 3 within 2 hours of rtPA bolus administration. Conclusion: The safety of low-dose argatroban combined with intravenous rtPA may be within acceptable limits, and its efficacy for producing fast and complete recanalization is promising, but a larger cohort of patients is required to confirm these preliminary observations. Trial Registration: clinicaltrials.gov Identifier: NCT00268762.

UR - http://www.scopus.com/inward/record.url?scp=33744482393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744482393&partnerID=8YFLogxK

U2 - 10.1001/archneur.63.8.1057

DO - 10.1001/archneur.63.8.1057

M3 - Article

C2 - 16908730

AN - SCOPUS:33744482393

VL - 63

SP - 1057

EP - 1062

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 8

ER -